Moderna mRNA Flu Vaccine Returns to FDA Review Track, With People 50 and Older as the First Focus

Flu vaccines are a science racing against time: viral strains change every year, yet manufacturing processes often need to begin months in advance. For that reason, if Moderna’s mRNA flu vaccine mFlusiva can pass U.S. regulatory review, its significance would lie not only in adding another product, but in whether the mRNA platform can extend its promise of “rapid design, rapid manufacturing” from the COVID-19 pandemic to seasonal respiratory diseases.

The U.S. FDA has scheduled a meeting of the Vaccines and Related Biological Products Advisory Committee for June 18, 2026, to discuss and vote on the safety and effectiveness of mFlusiva. According to the FDA meeting announcement, the vaccine’s proposed indication is the prevention of disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine in adults 50 years of age and older.

Investor's Business Daily reported that the pre-meeting briefing documents appeared not to identify major deficiencies in Moderna’s application, putting this mRNA flu vaccine, which had previously faced regulatory resistance, back on a path where approval may be possible. Based on the public documents, the FDA did not directly state an intention to approve before the meeting; the real regulatory signal will come from the committee’s discussion and vote on risk-benefit across different age groups.

The FDA briefing documents list mFlusiva as mRNA-1010 and state that Moderna submitted its biologics license application on December 5, 2025, and that it was accepted for review on February 17, 2026. The review design is divided into two pathways: adults ages 50 to 64 are seeking traditional approval; adults ages 65 and older are being discussed for accelerated approval, paired with a Phase 4 confirmatory study. This division shows that regulators are not simply asking whether the vaccine is effective, but are separately weighing the strength of evidence in different risk groups.

The core clinical data come from Moderna’s Study 304. The FDA summary states that, among adults 50 years of age and older, mRNA-1010 achieved 26.6% relative vaccine efficacy versus a standard-dose comparator vaccine against protocol-defined, RT-PCR-confirmed influenza-like illness; for higher-level medical care-related outcomes, the document lists relative efficacy of 47.9%. In its own briefing, Moderna said Study 304 enrolled 40,703 adults 50 years of age and older and met the prespecified efficacy criterion; Study 303 Part C enrolled another 2,992 adults 65 years of age and older as part of the data for the older population.

On safety, the FDA documents state that short-term solicited adverse reactions after mRNA-1010 vaccination were more common than with the comparator vaccine, consistent with the reactogenicity profile commonly seen with mRNA vaccines. However, measures including serious adverse events, deaths, and adverse events of special interest were generally balanced between the two groups; the documents also noted that no cases of myocarditis or pericarditis were observed within 42 days after vaccination. These data help reduce certain safety concerns, but they still cannot replace larger-scale, cross-season post-marketing monitoring.

**Background Context**

The appeal of mRNA flu vaccines lies in manufacturing flexibility. Traditional flu vaccines mostly rely on eggs or cell culture to amplify viruses, creating time pressure from strain selection to mass production; Moderna argues that the mRNA platform can avoid these viral culture steps, making it theoretically easier to respond to changes in circulating strains. However, platform advantages must be translated into actual clinical protection before they become a public health tool, rather than merely a manufacturing-side technology narrative.

The voting questions on June 18 also highlight the true focus of this review: the committee will vote separately on whether the benefits of mFlusiva outweigh the risks in adults ages 50 to 64 and in adults ages 65 and older. For Moderna, this is an important test as the mRNA platform moves beyond volatility in the COVID-19 vaccine market; for the flu vaccine field, it is a review that tests whether a new manufacturing process can secure a place in a mature but still imperfect prevention system.